Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias

The burden of atherosclerotic disease worldwide necessitates implementing the treatment of its risk factors. Among them, hypercholesterolemia has a central role. In addition to conventional small organic compounds and the recently introduced monoclonal antibodies, new technologies are arising such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gareri, Clarice, Polimeni, Alberto, Giordano, Salvatore, Tammè, Laura, Curcio, Antonio, Indolfi, Ciro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267663/
https://www.ncbi.nlm.nih.gov/pubmed/35807171
http://dx.doi.org/10.3390/jcm11133884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267663/
https://www.ncbi.nlm.nih.gov/pubmed/35807171
http://dx.doi.org/10.3390/jcm11133884

Ejemplares similares